CDEK
← All drugs Report issue

viomycin

Trade name: viocin

Small moleculeapproved

Approved

Jan 21, 1953

Viomycin is a basic peptide antibiotic, which is among the most effective agents against multidrug-resistant tuberculosis. The tuberactinomycins, such as Viomycin, target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. Specifically, viomycin binds to a site on the ribosome which lies at the interface between helix 44 of the small ribosomal subunit and helix 69 of the large ribosomal subunit. The structures of this complexes suggest that the viomycin inhibits translocation by stabilizing the tRNA in the A site in the pretranslocation state. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Jan 21, 1953

    Pfizer — Earliest FDA Approval

  2. Jan 21, 1953

    Pfizer — NDA Organization

Indications

Approved for

Mechanism of action

Approval history

  • approvedJan 21, 1953

Chemistry & pharmacology

Loading structure…

SMILES

NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@H]([C@H]2C[C@H](O)NC(N)=N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O
Mol. weight
685.7 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • celiomycin
  • florimycin
  • tuberactinomycin b
  • vinacetin a
  • viocin
  • viocin
  • viocin sulfate
  • viocin sulfate
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin
  • viomycin sulfate
  • viomycin sulfate
  • viomycin sulfate
  • viomycin sulfate

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
PfizerFor profitNDAJan 21, 1953
PfizerFor profitMKTG—